Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Clinigen Group plc: Transformational Year Delivers 25% Growth in Adjusted EPS*

Posted on: 29 Sep 16

BURTON-ON-TRENT, England--(BUSINESS WIRE)--Clinigen Group plc (AIM:CLIN, ‘Clinigen’ or ‘the Group’), the global pharmaceuticals and services group, has today published its full year results for the year ended 30 June 2016.


Adjusted gross profit* up 90%, driven by acquisitions and organic growth

Adjusted EPS* up 25% to 35.0p (2015: 28.0p)

Net debt decreased £8.1m to £68.1m, after £28.5m spent on acquisitions

Full year dividend increased 18% to 4.0p (2015: 3.4p)

Strongest performances by Specialty Pharmaceuticals, driven by revitalisation of newer products, and CTS

Integration of Idis and Link acquisitions substantially complete

Acquisition of Totect and Foscavir bag line extension enhances Specialty Pharmaceuticals portfolio

Shaun Chilton to become CEO on 11 November 2016, when Peter George steps down
(see separate announcement)

Peter George, Chief Executive Officer, said:

“The acquisition and integration of Idis and Link Healthcare have transformed the Group over the last 18 months.

“We have achieved our ambition to become the global market leader in the management and supply of both unlicensed and clinical trial medicines, and expanded our global footprint.

“Alongside the significant strategic progress, we have also delivered a strong financial performance with good levels of organic growth combining with the acquisitions to increase adjusted EPS* by 25%.

“The newer products in our Specialty Pharmaceuticals portfolio are making good progress, demonstrating the effectiveness of our revitalisation model and we saw another excellent year in the Clinical Trial Services division.”

Shaun Chilton, Chief Executive Officer-designate, added:

“We have started the new financial year well and are trading in line with our expectations.

“Our focus now is to capitalise on our international market leading positions and expanded geographical footprint, by driving organic growth and continuing to add to and progress the revitalisation of our products.”

For more information:

Editor's Details

Mike Wood

Last updated on: 29/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.